Updates to 'Call of Duty' for 'Warzone' and 'Modern Warfare' now support NVIDIA's DLSS, promising up to much higher frame rates in 4K.
Watch movies, play games, read books, rock out — and save $140. The sale ends today!
A jump to gaming could be fashion's biggest — and most lucrative — jump yet.
Paintings by Pablo Picasso, Piet Mondrian and Vincent Van Gogh went on display at Christie's in London on Thursday ahead of a May sale, with the auction house encouraging art fans to book viewings while museums remain closed in Britain. The sale will be led by Picasso's 1932 work "Femme assise près d'une fenêtre (Marie-Thérèse)", a portrait of the artist's mistress, which is seen selling around $55 million.
MONAT has been recognized on the Direct Selling News Global 100 list of top direct selling companies in the world and one of the Best Places to Work.
Veritas Announces Launch of EduSafe Pooled PCR Testing with Automatic Follow-Up For K-12 Schools, Childcare Centers and Summer Camps
VAZKEPA (icosapent ethyl) is the first and only authorized treatment for its cardiovascular risk reduction indication1,2,3 VAZKEPA authorization for Great Britain follows recent VAZKEPA authorization for European Union DUBLIN, Ireland and BRIDGEWATER, N.J., April 22, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted a Marketing Authorization for VAZKEPA (icosapent ethyl) as a treatment to reduce the risk of cardiovascular events in high cardiovascular risk statin-treated adult patients who have elevated triglycerides (≥150 mg/dL) and either established cardiovascular disease or diabetes, and at least one additional cardiovascular risk factor. The Great Britain Marketing Authorization for VAZKEPA applies to England, Scotland and Wales. Under the Brexit Northern Ireland agreement, the European centralized marketing authorization for the European Union covers Northern Ireland. The MHRA’s license swiftly followed the European Commission (EC) marketing authorization of icosapent ethyl for the European Union as announced on March 30, 2021.3 Amarin’s understanding is that icosapent ethyl is among the first products to be submitted and licensed through the MHRA’s new ‘reliance’ route following the end of the Brexit transition period. Icosapent ethyl has been identified as a new active substance with likely multi-factorial mechanisms of action.1 The MHRA authorization for VAZKEPA is based on over a decade of development and testing of icosapent ethyl, including efficacy and safety data from the REDUCE-IT® cardiovascular outcomes study.2 REDUCE-IT evaluated more than 8,000 high-risk patients who despite having their cholesterol levels well controlled by statin therapy remained at significant risk of heart attack, stroke, or other major adverse cardiovascular events (MACE), including death. As published, patients in the REDUCE-IT study had a median follow-up period of nearly five years. Results from this study, in which all patients remained treated with statins (and with other contemporary therapies) and where half the patients received icosapent ethyl and the other half received placebo, demonstrated a 25% relative risk reduction (p<0.001) in the first occurrence of MACE in the intent-to-treat patient population with use of icosapent ethyl (4 grams daily) compared with placebo. Professor Gabriel Steg, M.D., Chief, Department of Cardiology at Hôpital Bichat, Paris, commented, “The REDUCE-IT study shows icosapent ethyl could reduce CV events and has the potential to change the way residual cardiovascular risk is treated. This authorization of icosapent ethyl can make a difference to patients who are at high-risk of suffering from a heart attack or stroke. Eligible patients can be confident we have a new treatment that is backed by evidence-based data and European guideline recommendations.” The publication of this research has led to icosapent ethyl being recommended for use in high-risk statin-treated patients identified by moderately elevated triglycerides by 15 global medical societies around the world including the European Society of Cardiology and the European Atherosclerosis Society.4 Cardiovascular risk (CVD) is one of the leading causes of death in the United Kingdom, with heart and circulatory diseases causing more than a quarter (27%) of all deaths in the UK, which is more than 160,000 deaths each year.5 The marketing authorization is also timely in the wake of the COVID-19 pandemic, which has resulted in the reprioritization of clinical resources, often leaving patients with serious cardiovascular disease to delay much needed medical help.6 Preventative care is needed for at-risk patients with cardiovascular disease, including LDL-cholesterol management and additional treatments for statin-treated patients with residual cardiovascular risk, identified by elevated triglycerides and other risk factors, to address their unmet need. “Icosapent ethyl has been helping to reduce strokes, heart attacks and other major cardiovascular events in high-risk patients in the United States,” stated John Thero, president and chief executive officer of Amarin. “We are dedicated to the rethinking of cardiovascular disease risk reduction across Europe with an emphasis on preventative care. Amarin will work tirelessly throughout Europe to make icosapent ethyl available to all patients who may benefit from this important therapy.” In addition, the company announced that subsequent to the marketing authorization by the EC, the Norwegian Medicines Agency informed Amarin of its marketing authorization for VAZKEPA in Norway. Information regarding Amarin’s plans for commercialization and securing market access in Europe and the United Kingdom can be found in the FAQ section under investor relations at www.amarincorp.com. About Amarin Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our scientific research foundation to our focus on clinical trials, and now our commercial expansion, we are evolving and growing rapidly. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, and Zug in Switzerland as well as commercial partners and suppliers around the world. We are committed to rethinking cardiovascular risk through the advancement of scientific understanding of the impact on society of significant residual risk that exists beyond traditional therapies, such as statins for cholesterol management. About Cardiovascular RiskCardiovascular disease is the number one cause of death in the world. In the United States alone, cardiovascular disease results in 859,000 deaths per year.7 And the number of deaths in the United States attributed to cardiovascular disease continues to rise. In addition, in the United States there are 605,000 new and 200,000 recurrent heart attacks per year (approximately 1 every 40 seconds). Stroke rates are 795,000 per year (approximately 1 every 40 seconds), accounting for 1 of every 19 U.S. deaths. In aggregate, in the United States alone, there are more than 2.4 million major adverse cardiovascular events per year from cardiovascular disease or, on average, 1 every 13 seconds. Controlling bad cholesterol, also known as LDL-C, is one way to reduce a patient’s risk for cardiovascular events, such as heart attack, stroke or death. However, even with the achievement of target LDL-C levels, millions of patients still have significant and persistent risk of cardiovascular events, especially those patients with elevated triglycerides. Statin therapy has been shown to control LDL-C, thereby reducing the risk of cardiovascular events by 25-35%.8 Significant cardiovascular risk remains after statin therapy. People with elevated triglycerides have 35% more cardiovascular events compared to people with normal (in range) triglycerides taking statins.9,10,11 About REDUCE-IT®REDUCE-IT was a global cardiovascular outcomes study designed to evaluate the effect of VASCEPA in adult patients with LDL-C controlled to between 41-100 mg/dL (median baseline 75 mg/dL) by statin therapy and various cardiovascular risk factors including persistent elevated triglycerides between 135-499 mg/dL (median baseline 216 mg/dL) and either established cardiovascular disease (secondary prevention cohort) or diabetes mellitus and at least one other cardiovascular risk factor (primary prevention cohort). REDUCE-IT, conducted over seven years and completed in 2018, followed 8,179 patients at over 400 clinical sites in 11 countries with the largest number of sites located within the United States. REDUCE-IT was conducted based on a special protocol assessment agreement with FDA. The design of the REDUCE-IT study was published in March 2017 in Clinical Cardiology.7 The primary results of REDUCE-IT were published in The New England Journal of Medicine in November 2018.2 The total events results of REDUCE-IT were published in the Journal of the American College of Cardiology in March 2019.8 These and other publications can be found in the R&D section on the company’s website at www.amarincorp.com. About VASCEPA® (icosapent ethyl) CapsulesVASCEPA (icosapent ethyl) capsules are the first-and-only prescription treatment approved by the U.S. Food and Drug Administration (FDA) comprised solely of the active ingredient, icosapent ethyl (IPE), a unique form of eicosapentaenoic acid. VASCEPA was launched in the United States in January 2020 as the first and only drug approved by the U.S. FDA for treatment of the studied high-risk patients with persistent cardiovascular risk after statin therapy. VASCEPA was initially launched in the United States in 2013 based on the drug’s initial FDA approved indication for use as an adjunct therapy to diet to reduce triglyceride levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. Since launch, VASCEPA has been prescribed over ten million times. VASCEPA is covered by most major medical insurance plans. In addition to the United States, VASCEPA is approved and sold in Canada, Lebanon and the United Arab Emirates. In Europe, in March 2021 marketing authorization was granted to icosapent ethyl in the European Union for the reduction of risk of cardiovascular events in patients at high cardiovascular risk, under the brand name VAZKEPA. Indications and Limitation of Use (in the United States)VASCEPA is indicated: As an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥ 150 mg/dL) and established cardiovascular disease ordiabetes mellitus and two or more additional risk factors for cardiovascular disease. As an adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia. The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined. Important Safety Information VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components.VASCEPA was associated with an increased risk (3% vs 2%) of atrial fibrillation or atrial flutter requiring hospitalization in a double-blind, placebo-controlled trial. The incidence of atrial fibrillation was greater in patients with a previous history of atrial fibrillation or atrial flutter.It is not known whether patients with allergies to fish and/or shellfish are at an increased risk of an allergic reaction to VASCEPA. Patients with such allergies should discontinue VASCEPA if any reactions occur.VASCEPA was associated with an increased risk (12% vs 10%) of bleeding in a double-blind, placebo-controlled trial. The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel or warfarin.Common adverse reactions in the cardiovascular outcomes trial (incidence ≥3% and ≥1% more frequent than placebo): musculoskeletal pain (4% vs 3%), peripheral edema (7% vs 5%), constipation (5% vs 4%), gout (4% vs 3%), and atrial fibrillation (5% vs 4%).Common adverse reactions in the hypertriglyceridemia trials (incidence >1% more frequent than placebo): arthralgia (2% vs 1%) and oropharyngeal pain (1% vs 0.3%).Adverse events may be reported by calling 1-855-VASCEPA or the FDA at 1-800-FDA-1088.Patients receiving VASCEPA and concomitant anticoagulants and/or anti-platelet agents should be monitored for bleeding. Key clinical effects of VASCEPA on major adverse cardiovascular events are included in the Clinical Studies section of the prescribing information for VASCEPA as set forth below: Effect of VASCEPA on Time to First Occurrence of Cardiovascular Events in Patients with Elevated Triglyceride levels and Other Risk Factors for Cardiovascular Disease in REDUCE-IT VASCEPAPlaceboVASCEPA vs PlaceboN = 4089n (%)Incidence Rate (per 100 patient years)N = 4090n (%)Incidence Rate (per 100 patient years)Hazard Ratio (95% CI)Primary composite endpointCardiovascular death, myocardial infarction, stroke, coronary revascularization, hospitalization for unstable angina (5-point MACE)705(17.2)4.3901(22.0)5.70.75(0.68, 0.83)Key secondary composite endpointCardiovascular death, myocardialinfarction, stroke (3-point MACE)459(11.2)2.7606(14.8)3.70.74(0.65, 0.83)Other secondary endpointsFatal or non-fatal myocardial infarction250(6.1)1.5355(8.7)2.10.69(0.58, 0.81)Emergent or urgent coronary revascularization216(5.3)1.3321(7.8)1.90.65(0.55, 0.78)Cardiovascular death 174(4.3)1.0213(5.2)1.20.80(0.66, 0.98)Hospitalization for unstable angina 108(2.6)0.6157(3.8)0.90.68(0.53, 0.87)Fatal or non-fatal stroke98(2.4)0.6134(3.3)0.80.72(0.55, 0.93) Includes adjudicated cardiovascular deaths and deaths of undetermined causality. Determined to be caused by myocardial ischemia by invasive/non-invasive testing and requiring emergent hospitalization. FULL U.S. FDA-APPROVED VASCEPA PRESCRIBING INFORMATION CAN BE FOUND AT WWW.VASCEPA.COM. Forward-Looking Statements This press release contains forward-looking statements, including statements about the potential of VAZKEPA (known as VASCEPA in the United States) to favorably affect cardiovascular risk in appropriate patients and about making VAZKEPA available throughout Europe to patients who are at risk of a cardiovascular event. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties that may individually or together impact the matters herein and cause actual results, events and performance to differ materially from such forward-looking statements. Among the factors that could cause actual results to differ materially from those described or projected herein include the following: events that could impact future regulatory assessment, such as delays due to COVID-19 restrictions, later arising data, regulatory reviews and pricing assessments, and the successful implementation of commercialization plans or other information, events that could interfere with the grant or issuance of a patent, continued validity or enforceability of a patent; uncertainties associated with litigation generally and patent litigation specifically; Amarin's ability generally to maintain adequate patent protection and successfully enforce patent claims against third parties; and uncertainties associated generally with research and development and regulatory submissions, reviews, action dates and approvals. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent annual report on Form 10-K. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Amarin undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. Availability of Other Information About AmarinInvestors and others should note that Amarin communicates with its investors and the public using the company website (www.amarincorp.com), the investor relations website (investor.amarincorp.com), including but not limited to investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media, and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933. Amarin Contact InformationInvestor Inquiries:Investor RelationsAmarin Corporation plcIn U.S.: +1 (908) 719-1315 IR@amarincorp.com (investor inquiries) Solebury Troutamarinir@troutgroup.com Media Inquiries:CommunicationsAmarin Corporation plcIn U.S.: +1 (908) 892-2028 PR@amarincorp.com (media inquiries) AMARIN, REDUCE-IT, VASCEPA and VAZKEPA are trademarks of Amarin Pharmaceuticals Ireland Limited. VAZKEPA is a registered trademark in Europe and other countries and regions and is pending registration in the United States. 1Summary of Product Characteristics Vazkepa – April 2021 https://ec.europa.eu/health/documents/community-register/2021/20210326150935/anx_150935_en.pdf 2 Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380(1):11-22. 3 Union Register of medicinal products - Public health - European Commission. https://ec.europa.eu/health/documents/community-register/html/h1524.htm. Accessed April 22, 2021.4 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140-205.5 BHF/University of Birmingham calculated rates in partnership with UK statistical agencies: ONS/NRS/NISRA (2016-18 data)6 Fersia O, Bryant S, Nicholson R, et al. The impact of the COVID-19 pandemic on cardiology services. Heart. 2020;7:1359.7 American Heart Association. Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association. Circulation. 2020;141:e139–e596.8 Ganda OP, Bhatt DL, Mason RP, et al. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. J Am Coll Cardiol. 2018;72(3):330-343.9 Budoff M. Triglycerides and triglyceride-rich lipoproteins in the causal pathway of cardiovascular disease. Am J Cardiol. 2016;118:138-145.10 Toth PP, Granowitz C, Hull M, et al. High triglycerides are associated with increased cardiovascular events, medical costs, and resource use: A real-world administrative claims analysis of statin-treated patients with high residual cardiovascular risk. J Am Heart Assoc. 2018;7(15):e008740.11 Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease - New insights from epidemiology, genetics, and biology. Circ Res. 2016;118:547-563.12 Bhatt DL, Steg PG, Brinton E, et al., on behalf of the REDUCE-IT Investigators. Rationale and Design of REDUCE‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial. Clin Cardiol. 2017;40:138-148.13 Bhatt DL, Steg PG, Miller M, et al., on behalf of the REDUCE-IT Investigators. Reduction in first and total ischemic events with icosapent ethyl across baseline triglyceride tertiles. J Am Coll Cardiol. 2019;74:1159-1161.
Illinois American Water is awarding eight environmental grants focused on watershed initiatives across the state. The environmental grant recipients will receive a share of funds totaling $29,860 for community projects that improve, restore or protect watersheds.
The annual general meeting of shareholders of the Florence-based company has approved the appointment of Leonardo Ferragamo as non-executive chairman, succeeding his brother Ferruccio.
Toronto Blue Jays manager Charlie Montoyo used 7 pitchers in the victory against the Boston Red Sox and he explains his thinking behind several decisions within the game.
Hearing a bunch of petitions on dearth of COVID-19 essentials in the state, the The court also questioning the Maharashtra government over delay in RT-PCR test reports and said that it would direct government to increase the number of testing labs with approval from ICMR.
The euro edged higher, toyed with a bigger gain and then fell back after the European Central kept its interest rate policy intact and left questions about how it will withdraw stimulus when the economy recovers. The euro was up on the day about 0.1% against the U.S. dollar when the central bank posted its statement, and briefly doubled as ECB chief Christine Lagarde spoke afterward citing "signs of improvement" under clouds of economic uncertainty, before slipping back.
The organic producer AUGA group, AB (hereinafter the Company) is progressing with its employee motivation scheme through share options. The Company has made a decision to allocate a further 2.5 million shares to the employees and members of management bodies of the Company and its subsidiaries (hereinafter Employees). In total, since 2019 the Company will have allocated 7.2 million shares to its Employees. It also plans to assign a further more than 3 million shares for the same purpose in the future. The Company launched its first option programme in spring 2019. Almost 2.55 million shares were allocated to Employees in the first stage and additional 2.23 million shares in 2020. The programme is being continued this year, with the allocation of a further 2.5 million shares. A motion to approve an additional 1.7 million shares for future allocation, so that total unallocated number of Company shares intended for the option programme would reach 3 million shares, has been included in the agenda for the upcoming regular general meeting of the shareholders of the Company. If all accumulated reserves are allocated to employees and new shares are issued, they will amount to 3.66% of the equity of the Company. “While pursuing our ambitions goals in efficiency and sustainability as well as development of new technologies the key to success is our professional, engaged and motivated people. The option programme is being continued for the third consecutive year. It is motivating our valued employees who contribute the most to achieving company’s goals and we plan to remain committed to this programme in the future,” says Kęstutis Juščius, CEO of AUGA group, AB. The Company's share option programme is aimed at increasing Employee motivation and engagement. Shares are primarily granted to the Employees who make the highest impact on the success of the Company’s operations. Under existing agreement conditions, Employees are entitled to receive a specified number of Company shares after a period of 3 years. These shares are distributed to the Employees free of charge and funded by a Company reserve that has been formed for that purpose. CEOKestutis Juscius+370 5 233 5340
World Earth Day encourages people to support the protection of the planet.
One of the boys is “traumatized” and “a changed person,” officials said.
Yahoo Finance's Julie Hyman previews Berkshire Hathaway's Annual Shareholders Meeting.
A comedian called it racial profiling, but a police department working at Atlanta's airport describes what happened as a “consensual encounter.” Comedian Eric Andre on Wednesday told his 700,000-plus Twitter followers that he believed he had been racially profiled when officers pulled him aside in a terminal at Hartsfield-Jackson Atlanta International Airport and asked to search him for drugs. The Clayton County Police Department denies any wrongdoing, although it did not say why its officers chose to speak to Andre.
Travelling up residential streets in so-called Duncan, B.C., the houses become more elaborate as the elevation gets higher. At the end of a winding road, among immaculately-landscaped lawns, is an ancient Cowichan burial site known as Ye’yumnuts. On a Thursday afternoon, a small group of third-year law students from the University of Victoria (UVic)’s Juris Indigenous Doctorate (JID) program are engaged in a field school with Coast Salish law professor Sarah Morales, visiting the site. Nearby, an eagle circles over Ye’yumnuts — the burial site isn’t visible or marked from the surface level, so some residents might not know it exists right in their neighbourhood. That’s why Cowichan Tribes has started a project called ‘Commemorating Ye’yumnuts,’ an initiative aimed at educating the public about the some 2,000-year history of the site. The project and surrounding research are in partnership with UVic’s anthropology department and Cowichan Valley School District. Over three weeks in late March and into April, the UVic law students set up their day camp in the ancient village site to learn about Indigenous laws stemming from the land — with a larger goal of utilizing that knowledge as a way to protect other sacred areas. One day, students were guided up Mount Tzouhalem, where they learned about how the trees are an underground network that communicate and care for each other. Another day, the group practiced Hul’q’umi’num’ to make connections between language and law. Kayla Heath is a member of the Red Rock First Nation in Nipigon, Ontario, and a third-year law student in the JID program. She says she’s felt fortunate to be gifted with traditional knowledge from the area, from Elders who shared their teachings. The root word of Ye’yumnuts is “lum’” in Hul’qumi’num’, explains Cowichan Elder Luschiim (Arvid Charlie). Ye’yumnuts is located along the banks of the Somenos Creek, where at a time young boys would jump across it as a ceremonial way to determine if they were ready to be a man, he says. “You jumped across the creek and if you’re not ready as a man, a young man, when you landed your legs buckled and bent that’s a lum’,” says Luschiim in an educational video. “And if you land and you’re standing up you’ve proved your point,” he laughs. Education about sites like Ye’yumnuts and the living communities around them could motivate the wider public to want to protect the ancestors who are resting there, Heath says. “Right now [desecration] is happening because they are not seen as being real living breathing people with laws that are continuing in a modern context,” she says. “They are being seen as ancient remains or ancient sites, and it’s really not the case, [the communities are] still here.” Brian Thom, an anthropologist at UVic involved in the field school, has been doing work involving the Ye’yumnuts site since he was a grad student in 1994. Back then, he says, the site had been dug up during residential development, and he was asked to explore the site further. With 1,200 or so known ancestral burial sites in the territory of Hul’qumi’num-speaking peoples alone, the disturbance and desecration of sacred burial grounds by developers has been an ongoing problem across Vancouver Island. In late February, development in Cordova Bay outside of Victoria uncovered human remains from an ancestral burial site, Saanich Police confirmed. In March, a development on Hornby Island was halted after ancestral remains were found at the site, according to The Comox Valley Record. K’ómoks First Nation is now involved, with leadership saying that the issue lies with the province failing to enforce the B.C. Heritage Conservation Act, and not the developer. According to the B.C. government, there are more than 50,000 archaeological sites recorded in B.C. with hundreds being added to the list every year. “Every year in B.C. archaeological artifacts and sites are discovered by people out hiking, digging in their garden, doing home renovations, developing property, or working on the land base,” the province’s website states. The website also assures that archaeological sites on both public and private land are protected under the Heritage Conservation Act and must not be altered without a permit. Thom says in the 1970s, the provincial government hired archeologists to record archeological sites, but he says that mapping was done poorly and to his knowledge no one has ever completed thorough studies of these places. “The government has never funded that and most of this area is on private lands,” says Thom. Another important aspect missed when surveying was being completed is that Indigenous knowledge wasn’t taken into account, says Thom. Even today, he says, Indigenous Peoples are only being consulted “on a need-to-know basis.” Thom says he believes municipal governments can be part of the solution, if they take their own measures to protect and honour sacred sites. He says municipalities could do a better job at zoning, by flagging areas as sensitive when they have a high potential of uncovering a burial site, turning to evidence of oral histories. And when building permits are given, there should be precautionary measures in place that represent Indigenous values, he says. JID student Andrea Vogel, a settler from Treaty 6 Territory, agrees. As she stands at Ye’yumnuts, she says the main takeaway for her is that settlers must do more to fix the damage that has been done — and continues to be done — to Indigenous lands. “Settlers created this problem of non-recognition,” she says, adding that it is compounded by expectations of private property owners. “If we’re going to work from truth then the expectations need to shift.” Fellow student Heath elaborates on this point, and says the province focuses on protecting areas for environmental reasons but not as much for cultural ones. Even at Ye’yumnuts, which is a provincially-protected area, it was only designated as such because it’s now a conservation area for Garry Oak trees and the tall wooly head that was a red-listed endangered plant species. An environmentally protected area seems to be the tool that is working to stop development so far, says Vogel, “but the goal is to then actually have Cowichan Tribes jurisdiction here over their site.” Heath says what needs to happen is a larger, legislative change. “We need to see laws aligning with UNDRIP and DRIPA,” she says. “We need to see the Heritage Conservation Act administered differently because right now truly the language in it is designed to promote development and what it’s devoid of is language protecting cultural value.” The lack of recognition was felt on one of the last days of the field school, when a resident in the area apparently phoned the police on the group, saying they were trespassing. Prof. Morales says she was able to reason with the officer who arrived, and explain the misunderstanding, but recognizes the situation could have been different if not for the privileged position the university has. Many of the houses within close proximity to Ye’yumnuts were built before the discovery of human remains were documented, says Thom. Though the province asks people to report findings of archaeological sites or human remains, Thom says he believes that many private property owners are reluctant to report findings, because it would require an archaeological permit to continue development. “When we were doing our work in the ‘90s there were local residents reporting that they had archaeological findings in their homes — not human remains but artifacts,” he says. In 2016, a man doing renovations on his home in a residential area in Cadboro Bay in Greater Victoria discovered ancestral remains, according to the Cowichan Valley Citizen. The 13 people discovered were later identified by Lekwungen Tung’exw First Nation as being a part of a large family group that set up a permanent village in McNeil Bay and Willows Beach. Guy McNeill, whom the street is named after, was a proprietor of the Cadboro Bay Motel, apparently found no qualms in digging up gravesites around the property. An archive story in the Daily Colonist from 1963 indicates that McNeill and his sister dug up Indigenous skulls for “fun” and would later use them as “conversation pieces” in his motel. JID student Katie Mysak, who says she was raised in a blended family and grew up along the Winnipeg River in Anishinaabe Territory, says she is motivated to raise awareness about the ongoing disrespect to Indigenous burial sites. “If somebody went into a Western cemetery and dug up your grandma, there would be an uproar about that. So why is it any different that a developer can come in and dig up somebody else’s grandma and that’s OK and a permit can be granted for that?” she asks. “It doesn’t make any sense to me how those things can be so the same, but treated so differently, because it’s a different people.” “Editor’s note: This story was first published on April 21. This version corrects the naming of the tall wooly head.” Katłįà (Catherine) Lafferty, Local Journalism Initiative Reporter, The Discourse
HUHTAMÄKI OYJ STOCK EXCHANGE RELEASE 22.4.2021 AT 17:50 Transfer of Huhtamäki Oyj's own treasury shares A total of 15,000 of Huhtamäki Oyj's own treasury shares have today been transferred without consideration to the Company's President and CEO Charles Héaulmé as part of his remuneration. The directed issue is based on the authorization given by the Company's Annual General Meeting of 2021 and the decision by the Company's Board of Directors based on the authorization. After the transfer, Huhtamäki Oyj holds a total of 3,395,709 own treasury shares (3.15% of all shares). For further information, please contact: Mr. Sami Pauni, Executive Vice President, Corporate Affairs and Legal, Group General Counsel, tel. +358 (0)10 686 7872 HUHTAMÄKI OYJ Global Communications About Huhtamaki Huhtamaki is a key global provider of sustainable packaging solutions for consumers around the world, enabling wellbeing and convenience. Our innovative products protect on-the-go and on-the-shelf food and beverages, ensuring hygiene and safety, and help prevent food waste. We embed sustainability in everything we do. We are committed to achieving carbon neutral production and designing all our products to be recyclable, compostable or reusable by 2030. We are a participant in the UN Global Compact and as of 2020, we received an MSCI ESG Rating of A, on a scale of AAA ─ CCC. To play our part in managing climate change, we have committed to set science-based targets through the Science Based Targets initiative. Huhtamaki has been awarded the Silver medal by EcoVadis for performance in sustainability. With 100 years of history and a strong Nordic heritage we operate in 36 countries and 81 sites around the world. Our values Care Dare Deliver guide our decisions and help our team of 18,100 employees make a difference where it matters. Our 2020 net sales totaled EUR 3.3 billion. Huhtamaki Group is headquartered in Espoo, Finland and our parent company, Huhtamäki Oyj, is listed on Nasdaq Helsinki Ltd. Find out more about how we are protecting food, people and the planet on www.huhtamaki.com.
WILMINGTON, Del., April 22, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating BCTG Acquisition Corp. (“BCTG”) (NASDAQ GS: BCTG) regarding possible breaches of fiduciary duties and other violations of law related to BCTG’s agreement to merge with Tango Therapeutics, Inc. To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-bctg-acquisition-corp. You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or firstname.lastname@example.org. Rigrodsky Law, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide. Attorney advertising. Prior results do not guarantee a similar outcome. CONTACT: Rigrodsky Law, P.A.Seth D. RigrodskyGina M. Serra(888) 969-4242 (Toll Free)(302) 295-5310Fax: (302) email@example.com https://rl-legal.com